论文部分内容阅读
约50%的心力衰竭是由缺血性心脏病引起。血管新生疗法作为难治性缺血性心脏病的一种新疗法而受到关注。血管新生疗法中,有给予血管生长因子等方法,但其在双盲临床试验中的有效性尚未得到充分证实。另外,根据近年的研究,已经明确骨髓细胞可以产生各种各样的体液因子(VEGF、bFGF、PDGF等),并已知骨髓细胞中的未成熟干细胞会向血管内皮细胞等分化。而且,已经证明对缺血性心力衰竭模型进行骨髓细胞移植治疗后,可以增加血流,改善心功能。到目前为止,基于自体骨髓细胞移植的血管新生疗法正在世界各地进行尝试,并取得了良好的结果。但是,由于各个实验规模较小,且为短期观察,为确定该种治疗的有效性与安全性,仍需要大规模双盲临床试验来证实。期待今后自体骨髓移植的血管新生疗法有望成为缺血性心力衰竭的有效治疗方法。
About 50% of heart failure is caused by ischemic heart disease. Angiogenesis therapy is receiving attention as a new therapy for refractory ischemic heart disease. Angiogenesis therapy, there are methods such as giving blood vessels growth factors, but its effectiveness in double-blind clinical trials has not yet been fully confirmed. In addition, based on recent studies, it has been clarified that bone marrow cells can produce various humoral factors (VEGF, bFGF, PDGF, etc.), and that immature stem cells in bone marrow cells are known to differentiate into vascular endothelial cells. Furthermore, bone marrow cell transplantation in ischemic heart failure models has been shown to increase blood flow and improve cardiac function. To date, angiogenesis based on autologous bone marrow cell transplantation is being tried all over the world and good results have been achieved. However, due to the small size of individual experiments and short-term observations, large-scale double-blind clinical trials are still needed to confirm the efficacy and safety of this treatment. Looking forward to future autologous bone marrow transplantation of angiogenesis is expected to be an effective treatment of ischemic heart failure.